Responses

This article has a correction. Please see:

PDF

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Re:Re:EULAR advice against DMARD combination therapy, a major flaw.

    Dear Editor,

    We thank Dr. Smolen for commenting our criticism. As Dr. Smolen correctly states we did not pay attention to the fact that the EULAR recommendations (1) are based on 5 different systematic reviews. However, we assumed that the authors of the recommendations would attempt to reach an unambiguous position on the basis of the different reviews. Comparing the 15 recommendations in Table 1 with the treatment al...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Re:EULAR advice against DMARD combination therapy, a major flaw.
    • Josef S. Smolen, Rheumatologist
    • Other Contributors:
      • Robert Landewe, Laure Gossec, Simone Gorter, Cecile Gaujoux-Viala,

    Dear Editor,

    When writing their comment on the recent EULAR recommendations for the management of RA (1), Drs. Graudal and Jurgens must have overlooked several important aspects related to these recommendations. First, the set of recommendations was based on five separate systematic literature reviews (SLRs) and, indeed, items 5, 7 and 8 quoted by them are largely based on two of these 5 SLRs (2;3) rather than,...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    EULAR advice against DMARD combination therapy, a major flaw.
    • Niels A Graudal, senior consultant
    • Other Contributors:
      • Niels Graudal, Gesche Juergens

    Dear Editor,

    In point 5 and 7-8 of the EULAR recommendations for the management of rheumatoid arthritis (1) the following statements are listed:
    1) In DMARD naive patients, irrespective of the addition of GCs, synthetic DMARD monotherapy rather than combination therapy of synthetic DMARDs may be applied.
    2) If the treatment target is not achieved with the first DMARD strategy, addition of a biological DMARD s...

    Show More
    Conflict of Interest:
    None declared.